Flolan (Epoprostenol) by GlaxoSmithKline is given continuously through an indwelling catheter.
This study is ongoing, but not recruiting, as of 10-22-12:
Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH). This multicentre, open label, single-arm study in approximately 20 adult patients will evaluate the impact on lifestyle of a new thermo stable formulation of epoprostenol sodium in subjects with Pulmonary Arterial Hypertension (PAH). ClinicalTrials.gov.
A Randomized Controlled Trial of Epoprostenol Therapy for Severe Congestive Heart Failure: The Flolan International Randomized Survival Trial (FIRST). This study was for heart-failure patients (not PH patients), and the results were so bad the study was ended early, because the patients were dying off at an increased pace. Medscape.
SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to:
International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected] to request our Welcome email, or to report bad links or to update this page content.